DOCSLIB.ORG

TITLE Safety and Efficacy of Over-The-Counter Drug Use by the Elderly

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TITLE Safety and Efficacy of Over-The-Counter Drug Use by the Elderly " DOCUMENT RESUME ED 245 148 CG 017 518 TITLE Safety and Efficacy of Over-the-Counter Drug Use by the Elderly. Hearing before the Subcommittee on Health and Long-Term Care of the Select Committee on Aging. House of Representatives, Ninety-Eighth Congress, First Session. INSTITUTION Congress of the U.S., Washington, D.C. House Select Committee on Aging. REPORT NO House-Comm-Pub-98-409 PUB DATE 21 Jul 83 NOTE 507p.; Some pages are marginally legible due to small print. PUB TYPE Legal/Legislative/Regulatory Materials (090) EDRS PRICE MF02 Plus Postage. PC Not Available from EDRS. DESCRIPTORS *Consumer Protection; Dietetics; Drug Legislation; *Drug Use; Gerontology; Hearings; *Older Adults; Physical Health; *Safety IDENTIFIERS Congress 98th; Long Term Care; *Nonprescription Drugs; *PPA ABSTRACT This document contains the prepared statements and panel testimony from the Congressional hearing on over-the-counter (OTC) drug use by the elderly. Opening statements are given by Representatives Claude Pepper (chairman), Ralph Regula, Mary Rose Oakar, Michael Bilirakis, Tom Lantos, and Hal Daub. Topics which are covered include the incidence and quantity of drug use by the elderly, health risks, adverse reactions, phenylpropanolamine (PPA), consumer protection, and the Federal Drug Administration's (FDA) role in the OTC drug safety and reguIatiem. Testimony of the first panel on OTC drugs, particularly weight reduction medications containing PPA, is given by representatives of the Health Research Group, the National Broadcasting Company, and consumers. Testimony of the second panel on mail fraud schemes perpetrated against senior citizens is given by consumer advocates representing the United States Postal Service, Criminal Investigations and Consumer Protection Divisions, and the Center for Science in the Public Interest. Testimony of the third panel on evaluating the safety and efficacy of various drugs including PPA is given by medical experts from Georgetown, Indiana, Johns Hopkins, and George Washington Universities. Testimony of the fourth and final panel on the safety and efficacy of PPA is given by industry officials from the Thompson Medical Company, Inc., representing the fields of pharmacy, cardiology, sociology, psychology, and medicine. The three appendices contain additional material on medication use/abuse among the Pinellas County, Florida elderly, the FDA list of adverse drug reactions to PPA, the Washington State Board of Pharmacy review of OTC drugs, and prepared statements of panel representatives (BL) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made * * from the original document. * *********************************************************************** SAFETY AND EFFICACY OF OVER-THE-COUNTER co DRUG USE BY THE ELDERLY 4" (NJ HEARING BEFORE THE SUBCOMMITTEE ON HEALTH AND LONG-TERM CARE OF THE SELECT COMMITTEE ON AGING HOUSE OF REPRESENTATIVES NINETY-EIGHTH CONGRESS FIRST SESSION JULY 21, 1983 Printed for the use of the Select Committee on Aging Comm. Pub. No 98-409 _U,$DEPA_STMENT OF EDUCATION NATIONAL INSTITUTE_Of EDUCATION EDUCATIONAL_RESOURCES INFORMATION CENTER (ERIC) 7t, This document has been reproduced as received ;ram the person or organization originating it. Minor changes have been made to improve reproduction quality. Points of view or opinions stated in this doou: ment do not necessarily represent official NIE position or policy. U.S. GOVERNMENT PRINTING OFFICE 21-436 0 WASHINGTON : 1983 SELECT COMMITTEE ON AGING EDWARD R. ROYBAL, California,Chairman CLWIDE PEPPER, Flo, ,da MATTHEW J. RINALDO, New Jersey, If ACO BIAGGI, New York Ranking Minority lifern&er it ANDREWS, North Carolina JOHN PAUL HAMMERSCHMIDT, Arkansas .rstiNKER, Washington RALPH REGULA, Ohio 'T,I(')".'iAS J. DOWNEY, New York NORMAN D. SHUMWAY, California IA T. FLOR40, New Jersey OLYMPIA J. SNOWE, Maine TY.' )LL! E. FORD; Tennessee JAMES M. JEFFORDSVermont WILLiAM_J. HUGHES; New Jersey THOMAS J, TAUKE, Iowa MARILYN_ LLOYD ; Tennessee _ JUDD GREGG; New Hampshire srio; K . _LIINDINE_New York GEORGE C. WORTLEY, New York MARY ROSE OAKAR, Ohio HAL_DAUB,_Nebiliskti THOVA3 A. LUKEN, Ohio LARRY E. CRAIG, Idaho C'',..ALLYNP A. FERRARO, New York COOPER EVANS, Iowa nyv Et11, B. BYRON, Maryland JIM COURTER, New Jersey WILLI.? 1IR RATCHFORD, Connecticut LYLE WILLIAMS, Ohio DAN 1v1 A 'Florida C_ LAUDINE SCHNEIDER, Rhode Island HENTh A WAXMAN; California THOMAS J. RIDGE) Pennsylvania . "MAE Olerthorria JOHN McCAIN, Arizona KLITI L'R_1)L2KICK_:outh Carolina MICHAEL _BILIRAKIS, Florida BRUI.;F.-VEN-T0,-Miiinesota GEORGE WGEKAS, Pennsylvania BARNEY FRANK, Maana.r4-isetts MARK-D.-SILJANDER,_Michigan TOM LANTOS, Californin CHRISTOPHER H. SMITH, New Jersey RON WYDEN, Oregon MICHAEL DEWINE, Ohio DONA. Li JOSEPH ALB(Y7TA. Michigan GEC 'v. CROCAZETT, JR., MInhig_an WILLI d "ILL BONER; Tennessee IKE_S4IEr.:TON, Missouri DENN S_ N!, IICRT_EL, _Michigan ROBERT A BORSKL_Pennaylvaatia FREDERrii C. (RICK! BOUCHER, Virginia BEN ERDRE7CH, Alabama BUDDY MAr.KAY, Florida HARRY M. PEW., Nevada NORMAN SISISKY, Virginia TOM VANDERGRIFF, Tzxas ROBERT E-WISE _JR., West virgin:a BILL RICHARWON. N- Mr0 JOPC1' LAMBRINOS,Staff Director PAUL SCHLEGEIMinority Staff Director SUBCOMMITTEE ON HEALT:i AND LONG-TERM CARE CLAUDE PEPPER. Florida,Chairman IKE ANDREWS, North Carolina RALPH REGULA, Ohio, JAMES J. FLORIO, New Jersey Ranking Minority Member HAROLD E. FORD, Tennessee THOMAS J. TAUKE, Iowa MARILYN LLOYD-Tennessee GEORGE C. WORTLEY, New York MARY ROSE OAKAR; Ohio HAL DAUB; Nebraska THOMAS A; LUKEN; Ohio LARRY E. CRAIG, Idaho WILLIAN_R;_RATCHFORD,_Connecticut JIM COURTER; New Jersey BUTLER DERRICK; Sbuth Carolina THOMAS J, RIDGE; Pennsylvania RON WYDEN, Oregon JOHN MUCAIN,_ Arizona_ GERALDINE A. FERRARO, New York MICHAEL BILIRAKIS, Florida HENRY A. WAXMAN, California MICHAEL DEWINE, Ohio BRUCE F. VENTO, Minnesota MATTHEW J. RINALDO, New Jersey IKE SKELTON, Missouri (Ex Officio) DENNIS M. HERTEL, Michigan ROBERT A. BORSKI; Pennsylvania EDWARD R, ROYBAL; California (Eic Officio) BILL HALAMANDARIS,Staff Director KATHLEEN GARDNER CFtAVEDI,Assistant Staff Director JAMES P. OBERLE; Ph. D.;Minority Staff Director CONTENTS MEMBERS' OPENING STATEMENT Page Chairman Cla,.'',.'pler 1 Ralph Regula . 5 Mary Rose Oak, , ... 7 Michael Husk's 27 Tom Lantos 28 Hal Daub 30 CHRONOLOGICAL LIST OF WITNESSES Panel 1.Over-the-counter consumers and consumer representatives: Sidney Wolfe; M.D., director; Health Research Group; and president; Public Citizen 31 Anthea Sachs, Westport, Conn 38 Gloria Jean Davis, Albany, Ga. 38 Janey Phipps, R.N., Gray, Ky 39 Kathleen O'Reilley, consumer expert, National Broadcasting Co 41 Frank Adam°. Johnson Creek, Wis 45 Panel 2.Consumer advocates: Charles P. Nelson; Assistant Chief Postal Inspector, Criminal Investiga- tions Division; U.S. Postal Service, Washington, D,C. accompanied by George Davis, Assistant General Counsel, Consumer Protection Divi- sion of the Law Department, U.S. Postal Service 71 Bambi-Batts Young, Center for Science in the Public Interest, Washing- ton, D.0 76 Panel 3.Medical experts: Dr. Sorell Schwartz, professor of pharmacology, Georgetown University School of Medicine, Washington, D.0 85 Dr. Shirley Mueller, director of neurology, Reganstreif Health Center, Indiana University School-of _Medicine, Indianapolis, Ind 88 Dr. Thaddeus Prout, associate professor of medicine, Johns _Hopkins Uni- versity School of Medicine; and chief of medicine; Greater Baltimore Medical Center, Baltimore, Md 96 Dr. James Ramey, associate clinical professor at George Washington Uni- versity r.r. 101 Panel 4. Industry officials, Thompson Medical Co., Irm: Dr. Harold I. Silverman, prof&sor of pharmacy, Massachusetts college of Pharmacy and Allied Health Services 114 Dr. Matthew H. Bradley, cardiologist, Miami Heart Institute, Miami, Fla 116 Dr. Charles Winick, professor of sociology,_City University of New York 119 Dr, Rudolf E. Nobel; 'director, Cathedral Hill Obesity Clinic, San Francis- co, Calif 126 Dr. Anthony Conte, beriatrician; Beaver, Pa ... ..... -- ............ ------ 129 Dr. Marianne Sebok; physician, affiliated with J. F. Kennedy Memorial Hospital, Frankford Hospital, and Albert Einstein Memorial Center; Philadelphia, Pa 139 Dr.- Frank Funderburk, the Behavioral Pharmaceutical Research Unit of the Johns Hopkins University School of Medicine.. 147 Dr. Edgar E. Coons, Ph. D., professor of psychology, New York University 196 James Schreiber, Jr 220 James Schreiber, Sr 220 Barbara Ritz 221 Bill Iv APPENDIX Appendix 1."Medication Use/Abuse Among the Pinellas County Elderly,7 by Operation PAit, Inc. Elder/Ed program, Pinellas Park; Fla.,submitted Page for the record by Representative Michael Bilirakis 223 Appendix 2.Material submitted for the record by Representative MaryRose Oakar: Food and Drug Administration computer printnut listing 1,040 reported adverse drug reactions to products containing PPA 259 Background material dealing with -the Washington State Board of Phar- macy review of over-the-counter drug preparations 317 Appendix 3.Additional material received for the recorit Food and Mug Administration, Public Health vice; Department of Health and Human Services, prepared statement.. 351 Medical Society of the State of New York, Edward Siegel, M.D.,executive vice-preeident, letter 366 The Propprietary Association, Washington, D.C., Allan R. Reicinger, direc- tor of legislative relations, prepared statement 367 Thompson Medical -Co., Inc New York, N.Y., Edward L. Steinberg;M
Load more

Recommended publications
  • Mouth Rinses
    Mouth Rinses We may recommend a mouth rinse to you for one or more of the following reasons: Periodontal Disease, Gingivitis, Halitosis (bad breath), sensitive teeth, decay or increased risk of decay, dry mouth, minor mouth sore or irritation. Red= RX only Blue= Available through your dentist only Green= Over the counter *Common side effects found with many mouth rinses include the possibility of staining. We still encourage you to use the rinse that treats your problem because none of the stains these rinses cause are permanent. With good oral hygiene on your part, using your bleaching trays and bleach as needed, you can keep the staining to a minimum. If there is any staining that you can’t prevent, it can always be easily removed by your hygienist at your next cleaning. If you have periodontal disease or Gingivitis, we may recommend an antimicrobial/antiseptic type rinse. These rinses kill germs, reduce plaque, redness, swelling and bleeding when used in conjunction with proper brushing and flossing. Some common examples of antiseptic rinses are: Peridex or Perioguard oral rinses are available by prescription only. Active ingredient is chlorhexidine gluconate .12%. These also contain alcohol 11.6%. Can cause staining of the teeth*, taste alteration and dry mouth. Periomed Oral rinse is available through your dentist only. Active ingredient is stannous fluoride .63%. It is alcohol free. Periomed provides antimicrobial activity for up to 8 hours. Also promotes enamel remineralization, and helps reduce sensitivity. Can cause staining* and dry mouth. Listerine Antiseptic: Active ingredient is alcohol 26.9% in the original gold Listerine, and 21.6% in the other flavors.
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • No. 33981 2 No
    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
    [Show full text]
  • Listerine Floss Product Chart EN V9black
    RECOMMEND LISTERINE® EFFECTIVE MOUTHRINSES FOR A WHOLE MOUTH CLEAN® 3 ANTISEPTIC ANTICAVITY 2X MORE HEALTHY SITES VS. JUST BRUSHING & FLOSSING WHITENING ALL-IN-ONE ONLY LEADING BRAND THAT THE MOST COMPLETE RINSE WHITENS & STRENGTHENS ALL-IN-ONE ZERO ALL-IN-ONE ANTI-CAVITY PEROXIDE WHITENS AND WHITENS AND CLASSIC ANTI-STAIN ANTI-TARTAR ANTI-CAVITY ALL-IN-ONE FOR SENSITIVE ALCOHOL TEETH ZERO ALCOHOL ZERO ALCOHOL FREE STRENGTHENS STRENGTHENS METERED DOSING FOR KIDS FEATURES ® LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE LISTERINE TOTAL CARE HEALTHY HEALTHY HEALTHY ULTRACLEAN ULTRACLEAN ULTRACLEAN TOTAL CARE SMART RINSE ZERO TOTAL CARE FOR SENSITIVE WHITE™ WHITE™ WHITE™ BRAND ANTI-STAIN ANTI-TARTAR ANTI-CAVITY TEETH ZERO FOR KIDS GENTLE RESTORING VIBRANT COOL MINT BERRY FRESHBURST ARCTIC MINT BUBBLE GUM FLAVOURS MILD MINT COOL MINT FRESHBURST CLEAN MINT CLEAN MINT MILD MINT CLEAN MINT CLEAN MINT CLEAN MINT ORIGINAL COOL CITRUS MINT EUCALYPTOL 0.091% W/V MENTHOL 0.042% W/V THYMOL 0.063% W/V SODIUM FLUORIDE SODIUM SODIUM 0.02% W/W FLUORIDE FLUORIDE ACTIVE SODIUM FLUORIDE 0.022% W/V SODIUM TETRAPOTASSIUM 0.022% W/V 0.02% W/W FLUORIDE PYROPHOSPHATE INGREDIENTS ZINC CHLORIDE 0.09% W/V ZINC CHLORIDE POTASSIUM ZINC CHLORIDE 0.022% W/V PENTASODIUM HYDROGEN PEROXIDE 0.09% W/V NITRATE 2.4% W/V 0.09% W/V TRIPHOSPHATE KILLS UP TO 99.9% OF GERMS IN YOUR MOUTH PREVENTS & REDUCES GINGIVITIS PREVENTS & REDUCES PLAQUE SAFELY WHITENS TEETH† PREVENTS CAVITIES MILD FLAVOUR HELPS KEEP PREVENTS CAVITIES PRODUCT TEETH WHITE STRENGTHENS STRENGTHENS TOOTH ENAMEL* 2X BETTER TOOTH ENAMEL CAVITY ATTRIBUTES PROTECTION VS.
    [Show full text]
  • Mcneil Consumer : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
    [Show full text]
  • July 21, 2021
    1 2nd Quarter 2021 Earnings Call July 21, 2021 Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact
    [Show full text]
  • Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of
    PUBLIC COPY Notice under s66 of the Commerce Act 1986 Application by Johnson & Johnson to acquire the stock, assets and business of the Consumer Healthcare division of Pfizer Inc. COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE 28 September 2006 The Registrar Business Acquisitions and Authorisations Commerce Commission PO Box 2351 Wellington Pursuant to s66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. 518689_1.DOC 2 CONTENTS EXECUTIVE SUMMARY PART 1: TRANSACTION DETAILS 1 The business acquisition for which clearance is sought 2 The person giving this notice 3 Confidentiality 4 Participants 5 Interconnected and associated persons 6 Beneficial interests 7 Links between participants 8 Common directorships 9 Business activities of the participants 10 Reasons for the proposed acquisition PART II: IDENTIFICATION OF MARKETS AFFECTED 11 Horizontal aggregation 12 Differentiated product markets 13 Differentiated product markets 14 Vertical integration 15 Other business acquisitions PARTS III, IV AND V: CONSTRAINTS ON MARKET POWERS BY EXISTING AND POTENTIAL COMPETITION AND OTHER POTENTIAL CONSTRAINTS 16 Allergy medication 17 Products for the treatment of worms 18 Thrush treatment CERTIFICATE APPENDICES 1. Heartburn and indigestion remedies (MYLANTA and MOTILIUM) 2. Worm treatments (COMBANTRIN, VERMOX) 3. Cold, flu, nasal decongestant, cough relief and sort throat medications (CODRAL, SINUTAB, SUDAFED, BENADRYL, BRONDECON) 4. Allergy relief products (ACTIFED, SINUTAB, SUDAFED, VISINE, LIVOSTIN) 518689_1.DOC 3 5. Thrush treatments (DIFLUCAN ONE, DAKTARIN, DAKTAGOLD, NIZORAL, SPORANOX) 6. Shampoo (PREGAINE, ROGAINE, NEUTROGENA, JOHNSON’S BABY SHAMPOO) 7. Hand hygiene (PURELL and MICRO SHIELD) 8. Competitor worm treatment products 9. Multinational pharmaceutical businesses: GlaxoSmithKline, Douglas Pharmaceuticals, Alphapharm, Bayer Group 10.
    [Show full text]
  • Medication Code Key: PMCODE and Drug Name in 2007 NHHCS Cdc-Pdf
    Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00002 TAMIFLU 00003 DITROPAN XL II 00004 LIDODERM PATCH 00008 VIACTIV 00010 A AND D II 00013 MYCOPHENOLATE MOFETIL 00017 SIROLIMUS 00019 HAWTHORN 00027 SYNAGIS 00032 EXCEDRIN MIGRAINE 00036 MAALOX PLUS 00037 ACEON 00038 GLYSET 00039 SONATA 00042 PROTONIX 00044 PANLOR DC 00048 MOBIC 00052 SILDENAFIL CITRATE 00053 TAMSULOSIN HYDROCHLORIDE 00054 COMTAN 00058 MINERAL SUPPLEMENT 00061 BISMUTH 00071 CERTAVITE 00073 LUXIQ 00075 SAL-TROPINE 00076 TRILEPTAL 00078 AGGRENOX 00080 CARBIDOPA-LEVODOPA 00081 EXELON 00084 PREGABALIN 00085 ORAMORPH 00096 OSTEO-BIFLEX 00099 ALOCRIL 00100 A.S.A. 00101 ISOSORBIDE DINITRATE 00102 ISOSORBIDE MONONITRATE 00107 ROSIGLITAZONE MALEATE 00109 URSODIOL 00112 MEDERMA 00113 ANDROGEL 00114 DILTIA XT 00117 CRANBERRY 00123 NICOTINE 00125 AVELOX 00132 CAL-MAG 00133 CANDESARTAN Page 1 Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00148 PROLIXIN D 00149 D51/2 NS 00150 NICODERM CQ PATCH 00151 TUSSIN 00152 CEREZYME 00154 CHILDREN'S IBUPROFEN 00156 PROPOXACET-N 00159 KALETRA 00161 BISOPROLOL 00167 NOVOLIN N 00169 KETOROLAC TROMETHAMINE 00172 OPHTHALMIC OINTMENT 00173 ELA-MAX 00176 PREDNISOLONE ACETATE 00179 COLLOID SILVER 00184 KEPPRA 00187 OPHTHALMIC DROPS 00190 ABDEC 00191 HAPONAL 00192 SPECTRAVITE 00198 ENOXAPARIN SODIUM 00206 ACTONEL 00208 CELECOXIB 00209 GLUCOVANCE 00211 LEVALL 5.0 00213 PANTOPRAZOLE SODIUM 00217 TEMODAR 00218 CARBAMIDE PEROXIDE 00221 CHINESE HERBAL MEDS 00224 MILK AND MOLASSES ENEMA 00238 ZOLMITRIPTAN 00239
    [Show full text]
  • Procedure Description Charge Amount 0302000014 ROOM MED
    Charge Procedure Description Amount 0302000014 ROOM MED SURG MOSU 1,040.00 0302000015 ROOM MED SURG PEDS 3,500.00 0302000033 OUT PATIENT BED MOSU 0.00 0302000035 ROOM INTERMEDIATE MOSU 2,055.00 0302000043 ROOM HOSPICE MOSU 805.00 0302000045 ROOM MED SURG W TELE MOSU 1,530.00 0302000050 OBSERVATION INTERM PER HR MOSU 97.00 0302002283 FECAL MANAGEMENT SYSTEM 694.00 0302010232 CATH INDWELL BLADDER SIMPLE 185.00 0302010304 OBSERVATION MS PER HR MOSU 60.00 0302010305 OBSERVATION TELE PER HR MOSU 71.00 0302010556 NONBILLABLE OBSERVATION HR 0.00 0302010557 OBSERVATION DIRECT ADM MOSU 130.00 0302020287 SUPPLIES CHEST TUBE 228.00 0302050318 LUMBAR PUNCTURE DIAGNOSTIC 1,035.00 0302050451 IV INF THERAPEUTIC EA ADD HR 170.00 0302050453 IV INF THERAPEUTIC UP TO 1HR 635.00 0302050454 IRRIGATION BLADDER 780.00 0302050480 INSERT VENOUS CENTRAL LINE 1,315.00 0302050490 IV PUSH INITIAL DRUG 380.00 0302050534 I&D ABSCESS SIMPLE 675.00 0302050603 IV PUSH EA SEQUENTIAL DRUG 153.00 0302050648 HEMODIALYSIS SERVICE IP 1,455.00 0302050813 ARTHROCENTESIS MAJ JNT WO IMAG 630.00 0302050885 ADMIN IMMUNIZATION 145.00 0302050948 DIALYSIS INTRAPERITONEAL SERV 655.00 0302060002 INJECTION SUB-Q/IM 155.00 0302060008 CHEMO ADMIN IV INF EA ADD HR 410.00 0302060101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0302060269 US PV RESIDUAL URINE 240.00 0302060274 IV PUSH EA ADD DRUG 168.00 0302060275 IV INF CONCURRENT THERAPEUTIC 385.00 0302060276 IV INF SEQUENTIAL THER UP TO 1 191.00 0302060293 INSERT STRAIGHT CATH THERAPEUT 185.00 0302060372 CHEMO ADMIN IV INF SEQ 1 HR 525.00 0302060373
    [Show full text]
  • Milestone Guide and Workbook
    Tulsa County Family Treatment Court Milestone Guide and Workbook 6th Edition May 2019 Tulsa County Family Treatment Court Table of Contents Milestone 0 Orientation Milestone 0 Checklist 3 Family Treatment Court Contract 4-6 Consent for Re-disclosure of Confidential Information 7 Medical Compliance Form 8 Family Treatment Court Countdown to Sobriety Worksheet 9 Drug Testing Program Requirements 10 Urine Analysis Collection Policy and Procedures 11 Courtroom Rules and Treatment Court Important Points to Remember 12 Client Information Sheet 13 Court Dress Code 14 Prescription Drug Policy 15-16 Doctors, Medicine, and Family Treatment Court Information 17 Approved Over the Counter Medication List 18 Milestone 1 White Belt Milestone 1 Checklist 19-20 Important Contact Information 21 Appointment Scheduler Worksheet 22 Rules for Mentees and Mentors 23-24 What are You Strengths? 25 Taking Care of Me 26 Appendix A 211 Information Packet Appendix B Narcotics Anonymous and Alcoholics Anonymous Meeting Information 2 Tulsa County Family Treatment Court Milestone 0 White Belt Orientation and Introduction Drug Test Color: Gold Completed orientation packet o Contract o Release of Confidential Information o Medical Compliance o Drug Testing Program Requirements o UA Collection o Client Information Sheet Received o Courtroom Rules o Dress Code o Prescription Drug Policy o Doctor, Medicine, and FTC info sheet Received White wrist band Issued FTC Guidebook binder Recognized to court. You starting court date is: Sober date: Your date to start drug testing is: The color line number is 918-596-8737 Drug testing is done at DATL o (2626 S. Sheridan, phone: 918-664-3285) 3 Tulsa County Family Treatment Court Family Treatment Court Contract I, _______________________________, have been accepted as a voluntary participant in the Tulsa County Family Treatment Court Program.
    [Show full text]
  • 2019 SMDP Biotech Training Agenda & Scholar Bios
    2019 SMDP Biotech 1-5 June PHILADELPHIA www.icpdprograms.org 2019 Scientist Mentoring & Diversity Program for biotechnology (SMDP Biotech) www.icpdprograms.org Training Session June 1-6, 2019 in Philadelphia, PA about the program who attends: the one-year career mentoring program pairs ethnically diverse post-baccalaureate students, graduate students and post-doctoral researchers with industry mentors who work at biotechnology and consumer healthcare companies. With their mentors, SMDP Biotech Scholars attend a 5-day training session to learn about career opportunities in industry and receive career coaching. SMDP Scholars and Mentors also attend The BIO International Convention. how to dress, what to bring: business attire with comfortable shoes. Scholars, bring 100 business cards and 10 copies of your resume. Mentors will need business cards too. Informal dinner where to go: SMDP training Scholars and Mentors you’re Host Hotel session day 1 already on the guest list, we Mentors you will arrange the bus leaves the leave J&J Consumer at 5:15pm your own accommodation host hotel at 6:30am Ladder 15, 1528 Sansom Street, Scholars a shared room Scholars you will be Philadelphia, PA 19102 reservation has already been introduced to your made for you at this location: Mentors at the Reading Terminal MarKet Philadelphia 201, 201 N. 17th training session The bus leaves from the SMDP J&J Consumer, Street, Philadelphia, PA 19103 training session at 11:30am 199 Grandview Road, Corner of North 12th Street “Celebration of Mentoring Skillman, NJ 08558 and Arch Street (South Bldg. SK1912) & Diversity” reception ($10 will be provided) (Saturday, June 1st at 6pm) SMDP training The BIO Intl Convention Scholars and Mentors you’re session day 2 registration information will be already on the guest list the bus leaves the provided during the SMDP The Pyramid Club, host hotel at 7am training session.
    [Show full text]
  • Creative Director 561.714.1585 Andy Mathurin
    Hello, I am: Looking for role as: Let’s Connect: Andy Mathurin Creative Director 561.714.1585 Associate Creative Director, [email protected] Brand Strategist New York What I do: PROFILE Brand Strategy Over 8 years leading branding and marketing concepts with career spanning 360 campaigns, broadcast, print, OOH, social, digital, video and experiential Identity Design across major worldwide brands. Energetic and a creative visionary offering Storytelling demonstrated expertise in all aspects of branding and strategy, with core focus Thought Leader on delivering business results. Team Builder Marketing WINS Project Management Successes have included winning several accounts for new business, resulting in agency being awarded Global Agency of the Year by AdAge & Adweek. Toolkit: AOR: Havas - Vascepa 2019, Havas - Alcon 2019, J3 - OGX 2018, UM - H&M 2017, UM - Sony 2017, BMW 2016, UM - Coca Cola 2016 Sketch XD Microsoft Office PROFESSIONAL EXPERIENCE Avocode 03.18 HAVAS | Manhattan, NY Photoshop Present Associate Creative Director Strategic partner, focusing on brand equity for healthcare and InDesign pharmaceutical brands. Responsible for new business and leading creative Illustration team/studio across all digital platforms (specializing in social). After Effects Brands include: Zicam, Alcon, GSK, NUCALA, TRELEGY, & ANORO. 09.14 Universal McCann Worldwide | Manhattan, NY 03.18 Personality: Associate Creative Director + Senior Art Director Hands-on leader in identity design. Champion participant in winning new Human business pitches. Guiding and advising clients on high-level executions. Confident Brands include: Sony Pictures, GoPro, McCormick, BMW... and more. Effective Communicator - Demonstrate strong leadership overseeing staff in the day-to-day projects Motivational Honest with Integrity - Deliver against demanding brand objectives and develop creative that Empathetic exceeds business needs, managing projects from concept through completion: timelines, budgets, schedules, etc.
    [Show full text]